EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections

Junjie Ding, Richard M Hoglund, Harry Tagbor, Halidou Tinto, Innocent Valéa, Victor Mwapasa, Linda Kalilani-Phiri, Jean-Pierre Van Geertruyden, Michael Nambozi, Modest Mulenga, Sebastian Hachizovu, Raffaella Ravinetto und 2 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13211 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Junjie Ding und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Quinolines, Amodiaquine, Antimalarials, Malaria, Falciparum. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artemisinin‐based combination therapy (ACT) is the first‐line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant patient populations. This study aimed to evaluate the PK properties of amodiaquine and its active metabolite, desethylamodiaquine, and piperaquine in women in their second and third trimester of pregnancy with uncomplicated P. falciparum infections. Eligible pregnant women received either artesunate‐amodiaquine (200/540 mg daily, n = 771) or dihydroartemisinin‐piperaquine (40/960 mg daily, n = 755) for 3 days (NCT00852423). Population PK properties were evaluated using nonlinear mixed‐effects modeling, and effect of gestational age and trimester was evaluated as covariates. 1071 amodiaquine and 1087 desethylamodiaquine plasma concentrations, and 976 piperaquine plasma concentrations, were included in the population PK analysis. Amodiaquine concentrations were described accurately with a one‐compartment disposition model followed by a two‐compartment disposition model of desethylamodiaquine. The relative bioavailability of amodiaquine increased with gestational age (1.25% per week). The predicted exposure to desethylamodiaquine was 2.8%–32.2% higher in pregnant women than that reported in non‐pregnant women, while day 7 concentrations were comparable. Piperaquine concentrations were adequately described by a three‐compartment disposition model. Neither gestational age nor trimester had significant impact on the PK of piperaquine. The predicted exposure and day 7 concentrations of piperaquine were similar to that reported in non‐pregnant women. In conclusion, the exposure to desethylamodiaquine and piperaquine was similar to that in non‐pregnant women. Dose adjustment is not warranted for women in their second and their trimester of pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesAmodiaquineAntimalarialsMalaria, FalciparumArtemisininsHumansFemalePregnancyAdultYoung AdultPregnancy Complications, ParasiticAdolescentDrug CombinationsModels, BiologicalPiperazines

Substanzen

QuinolinespiperaquineAmodiaquineAntimalarialsArtemisininsartenimoldesethylamodiaquineamodiaquine, artesunate drug combinationDrug CombinationsPiperazines

Autor:innen und Institutionen

  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • University of Health and Allied Sciences, Ho, Ghana.
  • Clinical Trial Unit Nanoro, Nanoro, Burkina Faso.
  • Department of Community and Environmental Health, Kamuzu University of Health Sciences, Blantyre, Malawi.
  • Global Health Institute, University of Antwerp, Antwerp, Belgium.

ORCID-Profile: Joel Tarning

Förderung

  • Wellcome Trust

Zitieren

APA

Ding, J., Hoglund, R. M., Tagbor, H., Tinto, H., Valéa, I., Mwapasa, V., Kalilani-Phiri, L., Van Geertruyden, J. P., Nambozi, M., Mulenga, M., Hachizovu, S., Ravinetto, R., D'Alessandro, U., & Tarning, J. (2024). Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13211

Vancouver

Ding J, Hoglund RM, Tagbor H, Tinto H, Valéa I, Mwapasa V, et al. Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13211

BibTeX
@article{Ding2024,
  author = {Ding, Junjie and Hoglund, Richard M and Tagbor, Harry and Tinto, Halidou and Valéa, Innocent and Mwapasa, Victor and Kalilani-Phiri, Linda and Van Geertruyden, Jean-Pierre and Nambozi, Michael and Mulenga, Modest and Hachizovu, Sebastian and Ravinetto, Raffaella and D'Alessandro, Umberto and Tarning, Joel},
  title = {Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13211}
}
Kostenlos starten →